Colon cancer (adjuvant) - capecitabine and oxaliplatin

Summary

Capecitabine and oxaliplatin are recommended as possible adjuvant treatments after surgery for stage III (Dukes’ C) colon cancer, when used in the following ways:

• capecitabine on its own
• oxaliplatin together with 5-fluorouracil and folinic acid.

The choice of treatment should be decided jointly by the individual and their doctors, after they have discussed the options. This discussion should cover any contraindications to the treatments (reasons why a particular medicine might not be suitable for the person), the possible side effects of the treatments, and the different ways they can be given. It should also take into account the person’s clinical condition and individual preferences.

Documents

For healthcare professionals

• TA100 Colon cancer (adjuvant) - capecitabine & oxaliplatin: Quick reference guide
• TA100 Colon cancer (adjuvant) - capecitabine & oxaliplatin: Guidance

For patients, carers and the public

• TA100 Capecitabine ac oxaliplatin fel rhan o driniaeth gynorthwyol ar gyfer canser y colon cam III (Dukes' C)
• TA100 Colon cancer (adjuvant) - capecitabine & oxaliplatin: Information for the public

Background information

• 2006/018 100th NICE technology appraisal guidance offers new hope for people with colon cancer

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• TA100 Colon cancer (adjuvant) - capecitabine & oxaliplatin: analysis of cost impact